

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
28 July 2022 (28.07.2022)



(10) International Publication Number
WO 2022/159791 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 14/47 (2006.01)
C07K 14/725 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2022/013458

(22) International Filing Date:

24 January 2022 (24.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/141,016 25 January 2021 (25.01.2021) US
63/270,414 21 October 2021 (21.10.2021) US

(71) Applicant: **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 210 West 7th St., Austin, Texas 78701 (US).

(72) Inventors: **REZVANI, Katy**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). **SHPALL, Elizabeth**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). **BASAR, Rafet**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). **ACHARYA, Sunil**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). **UPRETY, Nadima**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). **MARIN COSTA, David**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). **ENSLEY, Emily**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US).

(74) Agent: **EDDY, Sarah D.**; Norton Rose Fulbright US, LLP, 98 San Jacinto Blvd., Suite 1100, Austin, Texas 78701 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: CD27-EXTRACELLULAR DOMAIN CAR TO TARGET CD70-POSITIVE TUMORS

(57) Abstract: Embodiments of the disclosure encompass methods and compositions that utilize an anti-CD70 chimeric antigen receptor (CAR) that lacks an antibody or antibody fragment as part of the receptor, including as part of the antigen binding region of the CAR. In particular embodiments, instead of the CAR employing an antibody to bind CD70, the CAR molecule utilizes CD27, the receptor for the ligand CD70. In specific embodiments, the CAR comprises a truncated version of CD27 rather than full length CD27. In specific cases, the CAR lacks the CD27 transmembrane domain.

WO 2022/159791 A1